GRAIL1 Stabilizes Misfolded Mutant p53 through a Ubiquitin Ligase-Independent, Chaperone Regulatory Function.
Ray P, Jaiswal S, Ferrer-Torres D, Wang Z, Nancarrow D, Curtin M, Martinho MS, Lacy SM, Kasturirangan S, Thomas D, Spence JR, Truttmann MC, Lagisetty KH, Lawrence TS, Wang TD, Beer DG, Ray D.,

ZNF8 promotes progression of gastrointestinal cancers via a p53-dependent mechanism.
Zhang Y, Yang Y, Hou Y, Yan W, Zhang X, Huang X, Song Q, He F, Wang J, Sun A, Tian C.

The role of p53 in male infertility.
Li J, Huang X, Luo L, Sun J, Guo Q, Yang X, Zhang C, Ni B., Free PMC Article

Atox1-cyclin D1 loop activity is critical for survival of tumor cells with inactivated TP53.
Kuchur OA, Pogodaeva SS, Shcherbakova AV, Tsymbal SA., Free PMC Article

Temporal regulation of gene expression through integration of p53 dynamics and modifications.
Lu D, Faizi M, Drown B, Simerzin A, François J, Bradshaw G, Kelleher N, Jambhekar A, Gunawardena J, Lahav G., Free PMC Article

Working title: Molecular involvement of p53-MDM2 interactome in gastrointestinal cancers.
Yedla P, Bhamidipati P, Syed R, Amanchy R.

Disrupting the interaction between a p53 gain-of-function mutant and the transcriptional co-activator PC4 reverses drug resistance in cancer cells.
Mondal P, Roy KS, Bhagat SV, Singh S, Chattopadhyay A, Ghosh DD, Kundu TK, Roychoudhury S, Roy S.

The mitochondrial enzyme pyruvate carboxylase restricts pancreatic β-cell senescence by blocking p53 activation.
Yang Y, Wang B, Dong H, Lin H, Yuen-Man Ho M, Hu K, Zhang N, Ma J, Xie R, Cheng KK, Li X.,

Entrainment and multi-stability of the p53 oscillator in human cells.
Jiménez A, Lucchetti A, Heltberg MS, Moretto L, Sanchez C, Jambhekar A, Jensen MH, Lahav G.

Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
Hosonaga M, Habano E, Arakawa H, Kaneko K, Nakajima T, Hayashi N, Fukada I, Nakamura A, Haruyama Y, Maeda T, Inari H, Kobayashi T, Nakashima E, Ueno T, Takano T, Takahashi S, Ohno S, Ueki A., Free PMC Article

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al Ali N, Xicoy B, López-Cadenas F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Diaz Varela N, Platzbecker U, Haase D, Díez-Campelo M, Della Porta M, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D.

IFN-γ induces acute graft-versus-host disease by promoting HMGB1-mediated nuclear-to-cytoplasm translocation and autophagic degradation of p53.
Wang S, Cheng T, Chen X, Zeng C, Qin W, Xu Y., Free PMC Article

Targeting mutant p53: a key player in breast cancer pathogenesis and beyond.
Qayoom H, Haq BU, Sofi S, Jan N, Jan A, Mir MA., Free PMC Article

Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation.
Nian Z, Dou Y, Shen Y, Liu J, Du X, Jiang Y, Zhou Y, Fu B, Sun R, Zheng X, Tian Z, Wei H.

Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition.
Meng W, Yu S, Li Y, Wang H, Feng Y, Sun W, Liu Y, Sun S, Liu H.

17p13 (TP53) Deletions Are Associated With an Aggressive Phenotype but Unrelated to Patient Prognosis in Urothelial Bladder Carcinomas.
Kluth M, Hitzschke M, Furlano K, Plage H, Hofbauer S, Weinberger S, Ralla B, Fendler A, de Martino M, Roßner F, Schallenberg S, Elezkurtaj S, Lennartz M, Marx AH, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Koch S, Adamini N, Weischenfeldt J, Klatte T, Minner S, Simon R, Sauter G, Schlomm T, Horst D, Zecha H.

Deciphering Internal Regulatory Patterns within the p53 Core Tetramer: Insights from Community Network Analysis.
Zhou H, Yan S.

CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation-Mediated c-Myc Deubiquitylation to Facilitate Mutant TP53 Transcription.
Wang Z, Li Y, Yang J, Sun Y, He Y, Wang Y, Liang Y, Chen X, Chen T, Han D, Zhang N, Chen B, Zhao W, Wang L, Luo D, Yang Q., Free PMC Article

Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms.
Du KX, Wu YF, Hua W, Duan ZW, Gao R, Liang JH, Li Y, Yin H, Wu JZ, Shen HR, Wang L, Shao Y, Li JY, Liang JH, Xu W., Free PMC Article

Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer.
Huang X, Chen C, Lin Y, Wang C, Zhou X, Xu Y, Sun Q, Zhou Y., Free PMC Article

HADHA promotes glioma progression by accelerating MDM2-mediated p53 ubiquitination.
Chen R, Chen H, Hu C.

High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
Caponio VCA, Zhurakivska K, Mascitti M, Togni L, Spirito F, Cirillo N, Lo Muzio L, Troiano G.

Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis.
Tang Y, Fan Y., Free PMC Article

Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy.
Lind SM, Sletten M, Hellenes M, Mathelier A, Tekpli X, Tinholt M, Iversen N.

Genomic profiles of Japanese patients with vulvar squamous cell carcinoma.
Fujii E, Kato MK, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H., Free PMC Article